Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC (HiltonolTM). CDX-1401 is a fusion protein consisting of a fully human monoclonal antibody with specificity for the dendritic cell receptor DEC-205 linked to the NY-ESO-1 tumor antigen. The NY-ESO-1 antigen is expressed in a variety of cancer cells. Targeting protein antigens to the DEC-205 receptor on dendritic cells was pioneered by the late Ralph Steinman, MD, a member of Celldex's Scientific Advisory Board. Dr. Steinman received the 2011 Nobel Prize in Physiology or Medicine for his discovery of the dendritic cell and its role in adaptive immunity. In preclinical studies, CDX-1401 has been shown to induce potent and broad immunity. The Phase 1 study of CDX-1401 is the first clinical study to demonstrate that an off-the-shelf vaccine that targets dendritic cells in vivo through DEC-205 can safely lead to robust humoral and cellular immunity when combined with TLR agonists in cancer patients - overcoming a significant challenge in the development of protein based vaccines.

"In the CDX-1401 study, we were able to translate the important preclinical work led by Dr. Steinman's lab into clinical benefit, generating protein specific immunity including both antibody and T cell responses in patients with advanced cancers known to express NY-ESO-1. This is an important milestone for the field of targeted vaccine development and for the development of CDX-1401 specifically. Importantly, some patients had evidence of clinical benefit with significant stable disease and measurable tumor shrinkage, despite their advanced stage of metastatic disease. The ability to target proteins to dendritic cells represents a promising approach for the next generation of vaccines against pathogens and cancer," said Madhav V. Dhodapkar, MBBS, Arthur H. and Isabel Bunker Professor of Medicine and Immunobiology, Chief of the Section of Hematology at the Department of Internal Medicine and Clinical Research Program Leader of the Hematology Program at Yale Cancer Center and the lead investigator of the study.

"CDX-1401 is at the forefront of a new generation of off-the-shelf dendritic cell targeted vaccines that Celldex believes hold significant promise as a platform for protein-based vaccines," said Tibor Keler, PhD, Chief Scientific Officer of Celldex Therapeutics. "The immunological and clinical data demonstrated in this study clearly support continued investigation and we plan to study additional combination regimens of CDX-1401 in melanoma and other indications where we believe a dendritic cell vaccine regimen could play an important role. We expect that a study sponsored by the Cancer Immunotherapy Trials Network will be initiated in 2013."

The results from the Phase 1 study of CDX-1401 were presented in a poster session entitled, "A Phase 1 Trial of a Novel Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 in Combination with Toll-like Receptor Agonists" at the Society for Immunotherapy Annual Meeting on Friday, October 26, 2012 by Dr. Dhodapkar. The study was conducted at multiple centers including Yale Cancer Center, Henry Ford Hospital and Medical Group, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, Providence Portland Medical Center, Mount Sinai Medical Center and the Carolina BioOncology Institute.


Celldex Therapeutics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Experts urge FDA to include T cell responses when evaluating COVID vaccines